AdaptHealth Names Mark P. Johnson CFO

TL;DR

AdaptHealth names Mark P. Johnson as new CFO, effective July 1st. Zimmer out.

AI Summary

AdaptHealth Corp. announced on June 27, 2024, the appointment of Mark P. Johnson as Chief Financial Officer, effective July 1, 2024. Johnson previously served as interim CFO and brings extensive financial leadership experience to the role. The company also reported on the departure of its previous CFO, Richard L. Zimmer, and the election of new directors.

Why It Matters

The appointment of a permanent CFO is crucial for financial stability and investor confidence. Mark Johnson's experience may signal a strategic direction for AdaptHealth's financial management.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategy and performance.

Key Players & Entities

• AdaptHealth Corp. (company) — Registrant
• Mark P. Johnson (person) — Appointed Chief Financial Officer
• Richard L. Zimmer (person) — Departing Chief Financial Officer
• June 27, 2024 (date) — Date of Report
• July 1, 2024 (date) — Effective date of CFO appointment

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share AHCO The Nasdaq Stock Mar

Filing Documents

• tm2418661d1_8k.htm (8-K) — 33KB
• tm2418661d1_ex10-1.htm (EX-10.1) — 68KB
• tm2418661d1_ex99-1.htm (EX-99.1) — 6KB
• tm2418661d1_ex99-1img001.jpg (GRAPHIC) — 5KB
• 0001104659-24-077607.txt ( ) — 308KB
• ahco-20240627.xsd (EX-101.SCH) — 3KB
• ahco-20240627_lab.xml (EX-101.LAB) — 33KB
• ahco-20240627_pre.xml (EX-101.PRE) — 22KB
• tm2418661d1_8k_htm.xml (XML) — 4KB

02(b) and (e) Departure of Directors

Item 5.02(b) and (e) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 27, 2024, following discussions initiated by the Chief Executive Officer of AdaptHealth Corp. (the "Company") and members of the Company's board of directors (the "Board"), the Company and Joshua Parnes, the Company's President, mutually agreed that Mr. Parnes will resign from all positions that he holds with the Company and its affiliates, effective as of 11:59 p.m. E.D.T. on August 31, 2024 (the "Transition Date"), except that Mr. Parnes will continue to serve as a non-executive member of the Board until December 31, 2024 (the "Separation Date" and the period from the Transition Date to the Separation Date being referred to as the "Board Service Period"). In connection with foregoing, the Company entered into a transition and separation agreement with Mr. Parnes, dated July 2, 2024 (the "Transition Agreement") pursuant to which the parties agreed to treat Mr. Parnes' resignation as a termination by the Company without "cause" as of the Transition Date for purposes of his previously disclosed Employment Agreement with the Company, dated March 20, 2019 (the "Employment Agreement"), and any outstanding equity awards granted pursuant to the Company's Second Amended and Restated 2019 Stock Incentive Plan or any predecessor thereof (the "Plan"). Mr. Parnes will be entitled to receive the contractual severance set forth in the Employment Agreement on a termination by the Company without "cause", a prorated annual bonus for the 2024 fiscal year, subsidized COBRA coverage during the Board Service Period at the active employee rate, and his then-outstanding equity awards will be treated in accordance with the terms of the Plan and the applicable award agreements as though his employment was terminated by the Company without "cause" as of the Transition Date and without regard to his change in statu

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 2, 2024, the Company issued a press release announcing the events described in Item 5.02 above and Item 8.01 below. A copy of the press release is furnished as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01

Item 8.01 Other Events . Appointment of Dale Wolf as Chair of the Board The Board has appointed Dale Wolf as Chair of the Board effective July 1, 2024. Mr. Wolf has served on the Board since November 2019 and will assume the role from outgoing Chair Richard Barasch.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. d) Exhibits Exhibit No. Description 10.1 Transition Letter Agreement, between AdaptHealth Corp. and Joshua Parnes, dated July 2, 2024. 99.1 Press Release dated July 2, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: July 3, 2024 AdaptHealth Corp. By: /s/ Jonathan B. Bush Name: Jonathan B. Bush Title: General Counsel - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR